NASDAQ · GCTK
GlucoTrack, Inc.
Healthcare · Medical - Devices
$1.42▼ 13.72% ($0.22)today
As of 3:55 PM ET
Market cap
$1.13M
P/E
-0.01
EPS (TTM)
-$71.77
Next earnings
Aug 14, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
Data notes
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
- 10-yr revenue CAGR
- —
- Ending operating margin
- —
- Discount rate
- —
USD · Price used $1.42 · Price Oct 1, 7:55 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 98.54% over the last year. Free cash flow declined 13.52% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Free cash flow fell 13.52% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Return analysis
Company profile
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes.
Market multiples
Stock splits
Every 15 shares became 1
Every 60 shares became 1
Every 5 shares became 1
Every 13 shares became 1
Profitability & growth
Analyst consensus
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 14, 2026
Q3 FY26 · EPS est — · Revenue est —
View
Institutional Sentiment
GlucoTrack, Inc. · GCTK
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.